Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Desipramine hydrochloride
Drug ID BADD_D00613
Description Desipramine hydrochloride is a dibenzazepine-derivative tricyclic antidepressant (TCA). TCAs are structurally similar to phenothiazines. They contain a tricyclic ring system with an alkyl amine substituent on the central ring. In non-depressed individuals, desipramine does not affect mood or arousal, but may cause sedation. In depressed individuals, desipramine exerts a positive effect on mood. TCAs are potent inhibitors of serotonin and norepinephrine reuptake. Secondary amine TCAs, such as desipramine and nortriptyline, are more potent inhibitors of norepinephrine reuptake than tertiary amine TCAs, such as amitriptyline and doxepine. TCAs also down-regulate cerebral cortical β-adrenergic receptors and sensitize post-synaptic serotonergic receptors with chronic use. The antidepressant effects of TCAs are thought to be due to an overall increase in serotonergic neurotransmission. TCAs also block histamine-H1 receptors, α1-adrenergic receptors and muscarinic receptors, which accounts for their sedative, hypotensive and anticholinergic effects (e.g. blurred vision, dry mouth, constipation, urinary retention), respectively. See toxicity section below for a complete listing of side effects. Desipramine exerts less anticholinergic and sedative side effects compared to tertiary amine TCAs, such as amitriptyline and clomipramine. Desipramine may be used to treat depression, neuropathic pain (unlabeled use), agitation and insomnia (unlabeled use) and attention-deficit hyperactivity disorder (unlabeled use).
Indications and Usage For relief of symptoms in various depressive syndromes, especially endogenous depression. It has also been used to manage chronic peripheral neuropathic pain, as a second line agent for the management of anxiety disorders (e.g. panic disorder, generalized anxiety disorder), and as a second or third line agent in the ADHD management.
Marketing Status Prescription; Discontinued
ATC Code N06AA01
DrugBank ID DB01151
KEGG ID D00812
MeSH ID D003891
PubChem ID 65327
TTD Drug ID D01UTL
NDC Product Code 50742-113; 45963-345; 45562-1736; 62332-320; 0781-8974; 50742-112; 23155-582; 62332-318; 23155-581; 45963-346; 50742-114; 30698-019; 0781-8972; 30698-015; 46708-319; 0781-8976; 68788-7750; 45963-344; 0781-8975; 30698-021; 30698-011; 46708-316; 50742-116; 0781-8218; 30698-020; 46708-315; 45963-342; 45963-343; 72189-104; 62332-319; 50742-115; 23155-579; 30698-007; 23155-583; 23155-578; 45963-341; 46708-317; 50742-117; 63629-7596; 71335-1021; 0781-8973; 23155-580; 62332-317; 62332-315; 46708-320; 46708-318; 62332-316
Synonyms Desipramine | Desmethylimipramine | Demethylimipramine | Desipramine Hydrochloride | Hydrochloride, Desipramine | Norpramin | Ratio-Desipramine | Ratio Desipramine | Nu-Desipramine | Nu Desipramine | Pertofrane | Pertrofran | Pertofran | Petylyl | PMS-Desipramine | PMS Desipramine | Apo-Desipramine | Apo Desipramine | Novo-Desipramine | Novo Desipramine
Chemical Information
Molecular Formula C18H23ClN2
CAS Registry Number 58-28-6
SMILES CNCCCN1C2=CC=CC=C2CCC3=CC=CC=C31.Cl
Chemical Structure
ADR Related Proteins Induced by Drug
ADR Term Protein Name UniProt AC TTD Target ID PMID
Metabolic disorderActivity-regulated cytoskeleton-associated proteinQ9WV31Not AvailableNot Available
ADRs Induced by Drug
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Abdominal pain07.01.05.002--
Accommodation disorder06.02.04.001--Not Available
Agitation19.06.02.001; 17.02.05.012--
Agranulocytosis01.02.03.001--Not Available
Alopecia23.02.02.001--
Anxiety19.06.02.002--
Arrhythmia02.03.02.001--Not Available
Asthenia08.01.01.001--Not Available
Ataxia17.02.02.001; 08.01.02.004--
Atrioventricular block02.03.01.002--Not Available
Blood glucose decreased13.02.02.001--Not Available
Blood glucose increased13.02.02.002--Not Available
Breast enlargement21.05.04.001--Not Available
Cerebrovascular accident24.03.05.001; 17.08.01.007--
Confusional state19.13.01.001; 17.02.03.005--
Constipation07.02.02.001--
Coordination abnormal17.02.02.004--Not Available
Delusion19.10.01.001--
Diarrhoea07.02.01.001--
Disorientation19.13.01.002; 17.02.05.015--Not Available
Dizziness24.06.02.007; 17.02.05.003; 02.01.02.004--
Dry mouth07.06.01.002--
Dysgeusia07.14.03.001; 17.02.07.003--
Dyspepsia07.01.02.001--
Electroencephalogram abnormal13.07.03.001--Not Available
Eosinophilia01.02.04.001--
Extrapyramidal disorder17.01.02.007--
Face oedema23.04.01.004; 10.01.05.002; 08.01.07.003--
Fall12.01.08.002--
Fatigue08.01.01.002--
The 1th Page    1 2 3 4    Next   Last    Total 4 Pages